Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
ATMARINOMED6
Thu, 11.04.2024
Marinomed Biotech AG
Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico
Launch of new allergen-blocking nasal spray in Austria for the treatment of hay fever complements existing OTC product portfolio
Partner M8 Pharmaceuticals launches Carragelose nasal spray for the treatment of viral respiratory infectio [ … ]
Thu, 28.03.2024
Marinomed Biotech AG
Marinomed Biotech AG announces agreement with European Investment Bank (EIB) to defer repayments of the 2019 venture loan for 18 months
Agreement with the EIB provides for a deferral of all capital repayments for 18 months, while interest rates remain unchanged
Real estate lenders also agreed to suspend repayments for 18 months
Marinomed plans [ … ]
Tue, 26.03.2024
Marinomed Biotech AG
Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe
Gulf-region specialist GAIA Healthcare FZ LLC obtains license for the marketing of Carragelose nasal sprays
Expansion of Carragelose partner network in Eastern Europe with VitaPlus Kft.
Korneuburg, Austria, 26 March 2024 – Marinomed Biotech AG [ … ]
Tue, 26.03.2024
Marinomed Biotech AG
Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe
Gulf-region specialist GAIA Healthcare FZ LLC obtains license for the marketing of Carragelose nasal sprays
Expansion of Carragelose partner network in Eastern Europe with VitaPlus Kft.
Korneuburg, Austria, 26 March 2024 – Marinomed Biotech AG [ … ]
Fri, 01.03.2024
Marinomed Biotech AG
Marinomed Biotech AG: Lucia Ziegler new Head of Investor & Public Relations
Korneuburg, Austria, 1 March 2024 – Lucia Ziegler will take over the newly integrated "Investor & Public Relations" department at Marinomed Biotech AG (VSE:MARI) as of the beginning of March 2024. In addition to her previous PR tasks, Lucia Ziegler will also be res [ … ]
Wed, 14.02.2024
Marinomed Biotech AG
Marinomed Biotech AG announces preliminary revenue for 2023
Preliminary revenues eased as expected to € 9.2 m in 2023 (2022: € 11.3 m) due to reduced Carragelose order volumes caused by sufficient customer stock levels
Cash position at € 2.6 m; financial stability secured by cost-conscious cash management and convertible note funding program
O [ … ]
Wed, 07.02.2024
Marinomed Biotech AG
Marinomed Biotech AG with important progress for Carragelose in 2024
First patient enrolled in clinical study investigating the moisturizing effectiveness of Carragelose eye drops
Clinical data showing the effectiveness of Carragelose in alleviating allergic symptoms in patients with grass pollen allergy published in peer-reviewed International J [ … ]